Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

White House Press Secretary Karoline Leavitt told reporters that President Trump would be implementing tariffs on Canada, ...

The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...

Alvogen, Inc. is voluntarily recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches to the consumer ...